The Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) phase 3 programme demonstrated the efficacy of oral semaglutide versus placebo and active comparators (including empagliflozin, sitagliptin and liraglutide) in achieving glycaemic control and weight loss, with a safety profile consistent with the GLP-1RA drug class [10,11,12,13,14,15,16,17,18,19,20,21]
Benefits of Semaglutide: Effective Weight Reduction: Patients have experienced notable weight loss in clinical settings
While results vary, substantial benefits are seen over weeks of consistent treatment
MDL 3094 consolidates federal lawsuits against Novo Nordisk (maker of Ozempic, Rybelsus, Wegovy) and Eli Lilly (maker of Trulicity and Mounjaro)
After 52 weeks of follow-up, after the medication was withdrawn, the average weight loss was 5.6% with semaglutide and 0.1% with placebo
Assessment and monitoring: Be vigilant for signs that your diabetes management may be affected, including: Elevated blood glucose readings above your usual range Increased thirst or urination (signs of hyperglycaemia) Unusual fatigue or lack of energy Return of symptoms that were previously well-controlled If you experience severe symptoms such as persistent vomiting, severe abdominal pain, or signs of pancreatitis (rare but serious), seek urgent medical attention from your GP, NHS 111, or 999 as appropriate
